Related Experiment Video
Updated: May 31, 2026

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
Published on: January 18, 2018
Conestat alfa for the treatment of angioedema attacks
Benjamin Davis1, Jonathan A Bernstein
1University of Cincinnati College of Medicine, Department of Internal Medicine, Division of Immunology/Allergy Section, Cincinnati, OH, USA.
Insights
New treatments for hereditary angioedema (HAE) include conestat alfa, a C1 inhibitor replacement. Derived from transgenic rabbits, it offers a safe and effective alternative for acute HAE attacks.
Area of Science:
- Immunology
- Pharmacology
- Genetics
Background:
- Hereditary angioedema (HAE) is a rare genetic disorder characterized by recurrent swelling attacks.
- Current treatments for HAE involve C1 inhibitor (C1-INH) replacement therapies, with several new products recently approved.
- Plasma-derived C1-INH products carry a risk of infectious transmission.
Purpose of the Study:
- To review hereditary angioedema (HAE) and its treatment options.
- To focus on the bench-to-bedside development and clinical trial findings of conestat alfa, a novel C1-INH replacement therapy.
Main Methods:
- Review of existing literature on HAE and C1-INH replacement therapies.
- Analysis of preclinical and clinical trial data for conestat alfa.
- Comparison of conestat alfa with existing HAE treatments.
Main Results:
- Conestat alfa is a novel C1-INH replacement produced from transgenic rabbits, offering a potentially unlimited and safer source compared to plasma-derived products.
- Clinical trial data demonstrate that conestat alfa is safe and effective for treating acute HAE attacks.
- The unique production method eliminates concerns regarding infectious transmission associated with human plasma-derived therapies.
Conclusions:
- Conestat alfa represents a significant advancement in HAE treatment.
- Its rabbit-derived origin provides a distinct advantage in terms of supply and safety.
- Conestat alfa is a safe and effective therapeutic option for patients experiencing acute HAE attacks.
Abstract:
Recently, multiple C1 inhibitor (C1-INH) replacement products have been approved for the treatment of hereditary angioedema (HAE). This review summarizes HAE and its current treatment modalities and focuses on findings from bench to bedside trials of a new C1-INH replacement, conestat alfa. Conestat alfa is unique among the other C1-INH replacement products because it is produced from transgenic rabbits rather than derived from human plasma donors, which can potentially allow an unlimited source of drug without any concern of infectious transmission. The clinical trial data generated to date indicate that conestat alfa is safe and effective for the treatment of acute HAE attacks.
More Related Videos
08:44Continuous IV Infusion is the Choice Treatment Route for Arginine-vasopressin Receptor Blocker Conivaptan in Mice to Study Stroke-evoked Brain Edema
Published on: September 1, 2016
03:40Acupoint Catgut Embedding Therapy in Traditional Chinese Medicine for Managing Allergic Rhinitis
Published on: December 20, 2024
Related Concept Videos
Adrenergic Agonists: Therapeutic Uses
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and anaphylaxis:...
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Allergic Reactions: Anaphylaxis
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Antiasthma Drugs: β2-Adrenoceptor Agonists
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...